Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS)
- 2 February 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 1 (2) , 59-63
Abstract
Hematopoietic prostaglandin D synthase (HPGDS) is primarly expressed in mast cells, antigen-presenting cells, and Th-2 cells. HPGDS converts PGH2 into PGD2, a mediator thought to play a pivotal role in airway allergy and inflammatory processes. In this letter, we report the discovery of an orally potent and selective inhibitor of HPGDS that reduces the antigen-induced response in allergic sheep.Keywords
This publication has 22 references indexed in Scilit:
- Novel Prostaglandin D Synthase Inhibitors Generated by Fragment-Based Drug DesignJournal of Medicinal Chemistry, 2008
- Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseasesNature Reviews Drug Discovery, 2007
- Determinants of cysteine pKa values in creatine kinase and α1‐antitrypsinProteins: Structure, Function, and Bioinformatics, 2004
- New drugs for asthmaNature Reviews Drug Discovery, 2004
- Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulationPharmacology & Therapeutics, 2004
- Expression of prostaglandin D synthase and the prostaglandin D2 receptors DP and CRTH2 in human nasal mucosaProstaglandins & Other Lipid Mediators, 2004
- Prostaglandin D 2 as a Mediator of Allergic AsthmaScience, 2000
- Mediators of nasal blockage in allergic rbtisAllergy, 1997
- Release of Prostaglandin D2into Human Airways during Acute Antigen ChallengeNew England Journal of Medicine, 1986
- The Bronchoconstrictor Effect of Inhaled Prostaglandin D2 in Normal and Asthmatic MenNew England Journal of Medicine, 1984